PCIDB

KNApSAcK Metabolite C00038654

Metabolite

KNApSAcK Entry

id C00038654
Name Bryostatin 1
CAS RN 83314-01-6
Standard InChI InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28?,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1
Standard InChI (Main Layer) InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3

Cluster

Phytochemical cluster
KCF-S cluster No. 3229

Link

ChEMBL

By standard InChI
By standard InChI Main Layer CHEMBL281926 CHEMBL449158 CHEMBL1891118

KEGG

By LinkDB C05149

CTD

By CAS RN C046785

Species

Summary

Plant class

class name count

Family

family name count
Bugulidae 1

List (1)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Bugula neritina 10212 Bugulidae Metazoa

Human Protein / Gene in interaction

7 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P17252 Protein kinase C alpha type Alpha CHEMBL449158 CHEMBL999748 (1) CHEMBL2034153 (1)
0 / 0
Q05655 Protein kinase C delta type Delta CHEMBL449158 CHEMBL999750 (1) CHEMBL2034156 (1)
0 / 0
Q02156 Protein kinase C epsilon type Eta CHEMBL449158 CHEMBL2034157 (1)
0 / 0
O75496 Geminin Unclassified protein CHEMBL1891118 CHEMBL2114780 (1)
0 / 0
O94782 Ubiquitin carboxyl-terminal hydrolase 1 Enzyme CHEMBL1891118 CHEMBL1794467 (1)
0 / 0
P05771 Protein kinase C beta type Alpha CHEMBL449158 CHEMBL2034155 (1)
0 / 0
Q8IV61 Ras guanyl-releasing protein 3 Other cytosolic protein CHEMBL449158 CHEMBL2034158 (1)
0 / 0

CTD interaction (16)

compound gene gene name gene description interaction interaction type form reference
pmid
C046785 330 BIRC3
AIP1
API2
CIAP2
HAIP1
HIAP1
MALT2
MIHC
RNF49
c-IAP2
baculoviral IAP repeat containing 3 bryostatin 1 results in increased expression of BIRC3 mRNA increases expression
mRNA 14527959
C046785 933 CD22
SIGLEC-2
SIGLEC2
CD22 molecule bryostatin 1 results in increased expression of CD22 protein increases expression
protein 10741703
C046785 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) bryostatin 1 inhibits the reaction [Paclitaxel results in increased activity of CDK1 protein] decreases reaction
/ increases activity
protein 10516758
C046785 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 bryostatin 1 analog results in decreased expression of IL10 mRNA decreases expression
mRNA 15614042
C046785 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 bryostatin 1 results in decreased expression of IL10 mRNA decreases expression
mRNA 15614042
C046785 3593 IL12B
CLMF
CLMF2
IL-12B
NKSF
NKSF2
interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40) bryostatin 1 analog results in decreased expression of IL12B mRNA decreases expression
mRNA 15614042
C046785 3593 IL12B
CLMF
CLMF2
IL-12B
NKSF
NKSF2
interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40) bryostatin 1 results in increased expression of IL12B mRNA increases expression
mRNA 15614042
C046785 3687 ITGAX
CD11C
SLEB6
integrin, alpha X (complement component 3 receptor 4 subunit) bryostatin 1 results in increased expression of ITGAX protein increases expression
protein 10741703
C046785 5578 PRKCA
AAG6
PKC-alpha
PKCA
PRKACA
protein kinase C, alpha (EC:2.7.11.13) [bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCA protein affects cotreatment
/ decreases expression
protein 8892972
C046785 5578 PRKCA
AAG6
PKC-alpha
PKCA
PRKACA
protein kinase C, alpha (EC:2.7.11.13) bryostatin 1 results in decreased expression of PRKCA protein decreases expression
protein 8892972
C046785 5579 PRKCB
PKC-beta
PKCB
PRKCB1
PRKCB2
protein kinase C, beta (EC:2.7.11.13) [bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCB protein affects cotreatment
/ decreases expression
protein 8892972
C046785 5579 PRKCB
PKC-beta
PKCB
PRKCB1
PRKCB2
protein kinase C, beta (EC:2.7.11.13) [bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCB protein alternative form affects cotreatment
/ decreases expression
protein 8892972
C046785 5579 PRKCB
PKC-beta
PKCB
PRKCB1
PRKCB2
protein kinase C, beta (EC:2.7.11.13) bryostatin 1 results in decreased expression of PRKCB protein decreases expression
protein 8892972
C046785 5579 PRKCB
PKC-beta
PKCB
PRKCB1
PRKCB2
protein kinase C, beta (EC:2.7.11.13) bryostatin 1 results in decreased expression of PRKCB protein alternative form decreases expression
protein 8892972
C046785 5582 PRKCG
PKC-gamma
PKCC
PKCG
SCA14
protein kinase C, gamma (EC:2.7.11.13) [bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCG protein affects cotreatment
/ decreases expression
protein 8892972
C046785 5582 PRKCG
PKC-gamma
PKCC
PKCG
SCA14
protein kinase C, gamma (EC:2.7.11.13) bryostatin 1 results in decreased expression of PRKCG protein decreases expression
protein 8892972

Related Disease

Diseases related to CTD interactions

5 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D005221 C046785 Fatigue marker/mechanism
10741703
D007938 C046785 Leukemia therapeutic
15070760
D015451 C046785 Leukemia, Lymphocytic, Chronic, B-Cell therapeutic
10741703
D008228 C046785 Lymphoma, Non-Hodgkin therapeutic
10741703
D010146 C046785 Pain marker/mechanism
10741703